What are the current developments and clinical trials?
Several pharmaceutical companies and research institutions are actively developing therapies targeting the SIRPα-CD47 axis. Clinical trials are underway to evaluate the safety and efficacy of these agents in various types of cancer, including solid tumors and hematologic malignancies. Early results have been promising, showing enhanced immune responses and tumor regression in some patients.
